ALBHF:OTC-Alibaba Health Information Technology Limited (USD)

COMMON STOCK | Pharmaceutical Retailers |

Last Closing

USD 0.436

Change

0.00 (0.00)%

Market Cap

USD 8.29B

Volume

800.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-28 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
JDHIY JD Health International Inc

N/A

USD 12.19B
JDHIF JD Health International Inc

N/A

USD 10.00B
RADLY Raia Drogasil SA ADR

N/A

USD 7.12B
CLCGY Clicks Group Ltd

N/A

USD 5.27B
SHPPF Shop Apotheke Europe N.V

N/A

USD 3.20B
SAEYY Shop Apotheke Europe N.V

N/A

USD 2.88B
NOTR Nowtransit Inc

N/A

USD 0.55B
ZRSEF Zur Rose Group AG

N/A

USD 0.46B
PNPL Pineapple Express

N/A

USD 0.01B
RLLVF Relevium Technologies Inc

N/A

USD 5.33M

ETFs Containing ALBHF

CHIH 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.41% 67% D+ 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.41% 67% D+ 39% F
Trailing 12 Months  
Capital Gain -19.41% 67% D+ 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.41% 67% D+ 39% F
Trailing 5 Years  
Capital Gain -60.36% 71% C- 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.36% 71% C- 32% F
Average Annual (5 Year Horizon)  
Capital Gain -19.87% 29% F 13% F
Dividend Return -19.87% 29% F 12% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 49.22% 71% C- 52% F
Risk Adjusted Return -40.36% 33% F 16% F
Market Capitalization 8.29B 90% A- 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.